文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性医院环境下COVID-19近实时交通灯系统的开发与实施

Development and implementation of a COVID-19 near real-time traffic light system in an acute hospital setting.
PubMed 文献 · Emerg Med J · 2020-09-18
一句话结论基于急诊首次生命体征与CRP的交通灯系统可标记COVID-19入院患者中高比例的血栓栓塞、细胞因子风暴和ARDS风险,作者鼓励开展更大规模前瞻性研究。

该研究由单一信托机构的COVID-19响应控制指挥部设立报告团队与生物信息学人员,开发近实时交通灯系统,以支持临床与运营团队。系统尝试用年龄、性别及首次记录血压、呼吸频率、体温、心率、氧合指标和C反应蛋白识别血栓栓塞、细胞因子风暴和ARDS的预测因素,并先通过单顾问向临床医生传达。923例连续COVID-19阳性患者中,592例(64%)被标记血栓栓塞风险,241/923(26%)被标记细胞因子风暴风险,361/923(39%)被标记ARDS风险;急诊阶段342例(37.1%)符合血栓栓塞和细胞因子风暴标记。作者结论认为急诊预测因素识别出高比例有临床恶化风险的COVID-19入院患者,使加速照护能针对更可能获益者,并鼓励开展更大规模前瞻性研究。

要点

  • 923例连续COVID-19阳性患者中,592例(64%)被交通灯系统标记血栓栓塞风险。
  • 241/923(26%)被标记细胞因子风暴风险,361/923(39%)被标记ARDS风险。
  • 急诊阶段342例(37.1%)患者同时符合血栓栓塞和细胞因子风暴标记。
  • 318例(34.5%)接受血栓栓塞标记者中,49例(全部患者的5.3%)为疑似血栓栓塞、103例(11.1%)高风险、166例(18.0%)中风险。
  • 89例(9.6%)在急诊接受细胞因子风暴标记者中,18例(全部患者的2.0%)为疑似细胞因子风暴、13例(1.4%)高风险、58例(6.3%)中风险。

适用人群与场景

  • 急诊科连续就诊且COVID-19检测阳性的成人患者,纳入923例连续病例。
  • 早期入院患者被用于优化交通灯系统中的预测因素。

诊断标准与关键阈值

  • 交通灯预测输入变量为年龄、性别及首次记录的血压、呼吸频率、体温、心率、氧合指标和C反应蛋白。
  • 系统尝试基于上述生理测量和血液检查识别血栓栓塞、细胞因子风暴和ARDS的预测因素。

处置流程与药物剂量

  • 设立单一信托机构的COVID-19响应控制指挥部,并部署含生物信息学人员的报告团队开发近实时交通灯系统以支持临床和运营团队。
  • 交通灯结果最初通过单顾问向管理患者的临床医生传达。

研究设计与关键结果

  • 923例连续COVID-19阳性患者中,592例(64%)被标记血栓栓塞风险,241/923(26%)被标记细胞因子风暴风险,361/923(39%)被标记ARDS风险。
  • 急诊阶段342例(37.1%)患者符合血栓栓塞和细胞因子风暴标记。
  • 318例(34.5%)接受血栓栓塞标记的患者中,49例(全部患者的5.3%)为疑似血栓栓塞,103例(11.1%)为高风险,166例(18.0%)为中风险。
  • 89例(9.6%)在急诊接受细胞因子风暴标记的患者中,18例(全部患者的2.0%)为疑似细胞因子风暴,13例(1.4%)为高风险,58例(6.3%)为中风险。
  • 男性更可能接受特定的交通灯标记。

证据类型、等级与局限

  • 证据类型:单信托机构的质量改进/系统开发与实施项目。
  • 局限:原文未报告局限性;作者在结论中鼓励开展更大规模前瞻性研究。

对床旁实践的改变

  • 急诊首次生命体征和C反应蛋白可用于交通灯系统,标记COVID-19入院患者中血栓栓塞、细胞因子风暴和ARDS的高风险人群。
  • 标记结果可支持临床和运营团队加速照护针对更可能获益的患者。
  • 作者认为急诊预测因素识别出高比例有临床恶化风险的COVID-19入院患者,并鼓励开展更大规模前瞻性研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Common causes of death in COVID-19 due to SARS-CoV-2 include thromboembolic disease, cytokine storm and adult respiratory distress syndrome (ARDS). Our aim was to develop a system for early detection of disease pattern in the emergency department (ED) that would enhance opportunities for personalised accelerated care to prevent disease progression. A single Trust's COVID-19 response control command was established, and a reporting team with bioinformaticians was deployed to develop a real-time traffic light system to support clinical and operational teams. An attempt was made to identify predictive elements for thromboembolism, cytokine storm and ARDS based on physiological measurements and blood tests, and to communicate to clinicians managing the patient, initially via single consultants. The input variables were age, sex, and first recorded blood pressure, respiratory rate, temperature, heart rate, indices of oxygenation and C-reactive protein. Early admissions were used to refine the predictors used in the traffic lights. Of 923 consecutive patients who tested COVID-19 positive, 592 (64%) flagged at risk for thromboembolism, 241/923 (26%) for cytokine storm and 361/923 (39%) for ARDS. Thromboembolism and cytokine storm flags were met in the ED for 342 (37.1%) patients. Of the 318 (34.5%) patients receiving thromboembolism flags, 49 (5.3% of all patients) were for suspected thromboembolism, 103 (11.1%) were high-risk and 166 (18.0%) were medium-risk. Of the 89 (9.6%) who received a cytokine storm flag from the ED, 18 (2.0% of all patients) were for suspected cytokine storm, 13 (1.4%) were high-risk and 58 (6.3%) were medium-risk. Males were more likely to receive a specific traffic light flag. In conclusion, ED predictors were used to identify high proportions of COVID-19 admissions at risk of clinical deterioration due to severity of disease, enabling accelerated care targeted to those more likely to benefit. Larger prospective studies are encouraged.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Vizcaychipi MP, Shovlin CL, McCarthy A, et al. Development and implementation of a COVID-19 near real-time traffic light system in an acute hospital setting. Emerg Med J. 2020. PMID: 32948623. doi:10.1136/emermed-2020-210199

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。